Category
162 articles — page 9 of 14
Men with vitiligo face distinct challenges — beard patches, body hair concerns, cultural reluctance to seek help, and a different emotional landscape than women typically report. Here is what matters specifically for men with vitiligo.
Eyelid vitiligo is distinct from periorbital vitiligo and raises specific safety questions about which treatments can be used near the eyes. This guide covers what is safe, what is not, and how to approach treatment in this sensitive area.
Facial vitiligo is the highest-priority treatment target for most patients — and fortunately the area with the best treatment response. This comprehensive guide covers all treatment options, zone-specific considerations, and realistic outcomes.
Acral vitiligo on the feet and soles is among the hardest vitiligo to treat. This guide explains the biology behind poor treatment response, which approaches are worth trying, and what realistic outcomes look like.
Vitiligo on the hands and fingers is one of the most common and most treatment-resistant presentations. This guide explains why acral vitiligo is harder to treat, which approaches have the best evidence, and what realistic outcomes look like.
White marks on nails in vitiligo patients may or may not be related to their condition. Understanding what true nail involvement looks like, how to distinguish it from common white nail marks, and what it means for prognosis.
Vitiligo on the lips is visible, high-contrast, and treatment-resistant compared to facial skin. This guide covers why lip vitiligo is harder to treat, which treatments have the best evidence, and how to manage appearance in the meantime.
Scalp vitiligo raises specific questions about white hair patches, the intersection with alopecia areata, and how to apply phototherapy effectively to a hair-covered area. Here is what the evidence shows.
Thyroid disease is the most common comorbidity in vitiligo — affecting roughly 20% of vitiligo patients. Understanding the connection, knowing which tests to request, and monitoring appropriately can meaningfully affect your health outcomes.
Type 1 diabetes is the third most common comorbidity in vitiligo patients, sharing genetic susceptibility and immune mechanisms. Understanding the link, what to monitor, and how treatment choices interact across both conditions.
Leucoderma and vitiligo are often used interchangeably — especially in South Asian contexts — but they are not exactly the same thing. Here is the precise distinction, and why it matters for diagnosis and treatment.
Vitiligo and albinism both involve reduced skin pigmentation but are completely different conditions — different genetics, different mechanisms, different distribution, and different treatment implications. Here is the clear distinction.
